Scleroderma Lung Risk Test - Anti-Scl-70 Antibody Test

A serological test detects autoantibodies directed against topoisomerase I (Scl-70). These antibodies are highly specific for systemic sclerosis and are found in approximately 25–40% of patients with diffuse cutaneous systemic sclerosis. Their presence is associated with more active and aggressive disease, with a higher risk of interstitial lung disease (ILD) and diffuse cutaneous fibrosis.